Migraine, a condition which affects approximately 10% of the adult population, can have an extremely debilitating influence on a person's normal pattern of activity. Recent advances have been made in our understanding of the mechanisms involved in a migraine attack. The initiating events, whilst not being clearly defined, would appear to be neuronal in origin. However, much evidence now points towards the cranial vasculature as the source of migraine headache; neurogenic vasodilatation and oedema in these vessels lead to centrally directed sensory nerve activation, probably via the trigeminal nerve, and the perception of pain. For many years, ergotamine has been the mainstay of clinical treatment for migraine, despite uncertain efficacy and an array of associated adverse effects. However, the recently developed selective 5-HT J receptor agonist, sumatriptan, provides a novel, highly effective treatment for migraine, relieving both the headache and associated symptoms such as nausea, vomiting, photophobia and phonophobia. Sumatriptan has a good safety profile and is well accepted by patients. Its mode of action in migraine is thought to result from an effect at the level of the 'inflamed' pain sensitive cranial blood vessel to reduce sensory nerve activation. Future studies with sumatriptan, both in migraine and in other types of headache, should lead to a greater understanding of the aetiology and pathogenesis of headache.
Introduction
Migraine affects approximately 1O' Yo of the adult population, with about one-third of sufferers having two or more attacks each month; these attacks may last for up to 72 hours. I , 2 Despite the prevalence of migraine and the debilitating effect that a migraine attack may have on an affected person's normal pattern of activity, there is still little known about the mechanisms involved in the genesis of migraine and, until recently, little effective treatment available.
Ergotamine has represented the mainstay of clinical treatment for the acute attack, but with its variable efficacy and undesirable side effect profile, is far from the ideal agent. However, recent research has provided new insight into the pathophysiology of migraine headache'A and recent clinical studies have established the efficacy of sumatriptan, a selective 5-HT, receptor agonist.v" in the treatment of migraine.":" This review aims to summarize current views on the pathophysiology of migraine, highlighting the evidence for a vascular involvement in the headache phase. Additionally, the mechanism by which the novel agent, sumatriptan, alleviates the symptoms of migraine is discussed and the profile of action of sumatriptan compared with that of ergotamine. 
Diagnostic criteria for migraine headache
Before 1988, the diagnosis of migraine was based on the ad hoc committee criteria. J() These were imprecise and subject to variable interpretation. Published studies of headache included patients with various diagnoses which made the interpretation of clinical benefit in individual headache types unclear. However, in 1988 a committee of the International Headache Society (IHS) published a new classification system for headache disorders. II This allows migraine without aura (formerly common migraine) and migraine with aura (formerly classical migraine) to be more rigourously defined (Table 1) . Migraine headache is commonly throbbing or pulsating in nature, unilateral in location and between 4-72 hours in duration. Additionally, it is generally associated with photophobia and/or phonophobia, and nausea and/or vomiting. In migraine with aura, the characteristics of the aura, which precedes the headache by an interval of not greater than 60 minutes, are described in Table 1 . The introduction of this classification has provided an important impetus to clinical research on migraine by giving a sound and internationally agreed basis for diagnosis.
Pathogenesis of migraine
Despite a wealth of research over many years into the event of a migraine attack, it is still unclear what precise mechanisms are involved. Various hypotheses have been put forward involving vascular and neuronal changes. Many emanate from the pioneering work of Wolff in the 1930s and 1940s and his proposal of a vascular aetiology for migraine.P-'? However, this could not satisfactorily explain certain aspects of migraine'<" and recent evidence implicates neuronal rather than vascular changes as the initiating event. Quantitative measurement of regional cerebral blood flow (rCBF) in migraine patients using intracarotid 133xenon clearance shows a typical pattern of focal posterior hypoperfusion during the aura. The region of hypoperfusion gradually increases in size as the aura phase develops but this advancement does not follow the known distribution territories of At least three of the following four characteristics -One or more fully reversible aura symptoms indicating focal cerebral cortical and/or brain stem dysfunction At least one aura symptom develops gradually over more than four minutes or t wo or more symptoms occur in succession No aura symptom lasts more than 60 minutes. If more than one aura symptom is present. accepted duration is proportionally increased Headache follows aura with a free interval of less than 60 minutes (it may also begin before or simultaneously with the aura) the cerebral circulation.t-v-" Interestingly, the rate of advancement of the wave of hypoperfusion seems to correlate closely with that seen in animal studies after induction of spreading neuronal depression;" suggesting a neuronal rather than vascular primary event. 1.ln However, what actually initiates this focal posterior hypoperfusion is as yet unknown. Whether blood flow in the hypoperfused regions of the brain reaches ischaemic levels has been much discussed.ln. 17.19 It is argued that using the 133xenon technique, rCBF in low flow areas can be overestimated by as much as 50% because of an intrinsic error due to Compton scatter.!" Thus, transient ischaemia could occur in the low flow areas, resulting in the various neurological symptoms of the aura phase. Hypoperfusion continues into the headache phase, but gradually cerebral blood flow normalizes and may develop into hyperaemia. However, this occurs without any change in the headache or associated symptoms of migraine.i-" Indeed, in migraine without aura, no consistent change in rCBF can be detected." Therefore it is not possible to provide a pathophysiological explanation for the headache on the basis of changes in rCBF, regardless of whether migraine with or without aura is being considered.
Cranial blood vessels are innervated by a dense plexus of perivascular sensory nerves that can be activated by electrical stimulation, mechanical manipulation or distension of the vessel. 3.4.21.22 These nerves originate mainly from the trigeminal ganglion via the 5th cranial (trigeminal) nerve and sensory innervation to the large cranial arteries in the brain and meninges is particularly dense.s-» These vessels may be important in the pathophysiology of migraine headache. Indeed, a recent study combining measurement of rCBF and blood velocity in the middle cerebral artery (MCA), using single photon emission computerized tomography (SPECT) and transcranial Doppler sonography simultaneously, concluded that migraine headache is associated with large (conduit) intracranial artery distension.>' In a separate study, inflation of a balloon catheter in the MCA of patients undergoing embolization therapy caused a reproducible headache.F Interestingly, according to the exact position of the catheter, the pain in these patients was primarily referred to the temple, forehead or orbit, areas that are also innervated by the trigeminal nerve. This study demonstrates that stretching of an intracranial artery elicits headache and that the pain is referred to locations commonly associated with rnigraine.» This referral is probably mediated viã central convergence of trigeminal fibres mnervating intra-and extracranial structures, which connect to nociceptive brainstem neurones.v" It has been proposed that migraine headache results from a sterile, neurogenic inflammation of intracranial blood vessels and that this process is mediated via the trigeminal nerve.v' The initiating event for such a process has not been determined but it is thought likely to be a consequence of neuronal activity within the brain, possibly within the brain stem.i-" Nevertheless, the result is a change in neuronal tone to the cranial vasculature and vasodilatation. Local activation of trigeminal perivascular sensory nerves, via the initiation of antidromically Migraine, serotonin and sumatriptan 117 mediated local axon refl~xes. and subsequent further sensory nerve activation, leads to the development of 'neurogenic inflammation' within the cranial vasculature. Antidromic activation of the trigeminal nerve has been shown experimentally to cause the release of substance P and calcitonin gene-related peptide (CGRP) from perivascular nerve terminals.P'?" These agents are potent vasodilators of craniovaseular smooth. muscle and substance P additionally causes Increased vascular permeability, leading to plasma protein extravasation and oedema formation.4.23.2lJ-32 Once intracranial blood vessels are abnormally dilated and oedematous, one can envisage that this would cause activation of pressure-sensitive C-fibre trigeminal afferent fibres in the vessel wall. Transmission of this noxious information to the CNS consequently results in the perception of headache. Moskowitz's th eory3.4 can explain many of the features of migraine: its unilateral location, pulsating diffuse quality and the accompanying autonomic effects, which could result from the increased sensory input into the CNS. Additionally, this proposal is in keeping with rCBF data obtained during migraine (see previous section): this dilatation of large intracranial arteries would not be expected to affect cerebral blood flow since the large conduit vessels have little influence on vascular resistance. Some clinical evidence which supports the concept of overactivity within the trigeminal craniovascular system during migraine comes from the work of Goadsby et al," who found that plasma levels of CGRP in jugular venous blood from the headache side are significantly increased during migraine, compared to venous blood sampled peripherally, as well as that from normal controls ( Figure I ).
Migraine and serotonin
Serotonin (5-HT) has been implicated in the pathophysiology of migraine, since the original observation of Sicuteri et al," that levels of 5-hydroxyindolacetic acid (5-HIAA), the major metabolite of 5-HT, were increased in the urine during a migraine attack. Curran et al.> repeated this observation and also demonstrated that platelet levels of 5-HT were decreased by about Sumatriptan: clinical efficacy in the treatment of migraine and mechanism of action it seems unlikely that a change in circulating levels of 5-HT is a primary initiating event in migraine. First, it seems difficult to understand how changes in peripheral circulating levels of 5-HT could explain the characteristically unilateral headache. Secondly, the time course of the change in 5-HT levels does not correlate with the duration of the headache: 5-HT plasma levels can remain low for several days after cessation of the headache." However, recent reports that the cerebral circulation may receive a serotoninergic innervation, possibly arising from the dorsal raphe nucleus," provides a means by which locally released 5-HT could discretely affect vessel tone. Such discrete changes in 5-HT levels are unlikely to be detectable by measurement of plasma levels. Nevertheless it has been suggested that if 5-HT does have an aetiological role, it is likely to be due to central release of 5-HT within the brain and that the fall in plasma levels may merely be a reflection of such an event. 14 Additional evidence to implicate 5-HT in the aetiology of migraine comes from the observation that many antimigraine drugs interact with 5-HT receptors in some way, but again this may only be circumstantial. Thus ergotamine will activate several types of 5-HT receptorsv"; agents like pizotifen, cyproheptadine and amitryptyline, which are used as prophylactic treatments, are 5-HT2 receptor antagonists." However, all of these drugs have additional effects at other receptors and therefore it is difficult to draw any definitive conclusions about which receptor is important for their antimigraine activity.
Sumatriptan is a selective agonist for a certain subtype of 5-HT receptor, namely the 5-HT\ receptor subtype, which mediates vasoconstriction predominantly within the cranial vasculature. 5 ,I>,4 1 Thus sumatriptan contracts isolated cerebral arteries from animals and man and produces vasoconstriction of human isolated dura mater via activation of 5-HT\ receptors ( (Reproduced from Goadsby et al. 33 with kind permission from Little. Brown and Company.)
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during migraine headache. These observations have been confirmed by others and are claimed to be specific for migraine since similar changes are not seen with other stressful situations." Furthermore, reserpine and related drugs, which cause 5-HT depletion, will cause migraine-like headache in susceptible individuals (see \4 for references). The putative role of 5-HT in the aetiology of migraine has been recently comprehensively reviewed."
Together, these findings suggest that migraine may be associated with low circulating levels of 5-HT and interestingly, intravenous administration of 5-HT will alleviate migraine headache." However, evidence for an involvement of 5-HT in the aetiology of migraine is merely circumstantial and, for several reasons, vessels.v' This selectivity of sumatriptan for the cranial vasculature reflects the differential distribution of 5-HT receptors: 5-HT, receptors predominantly mediate contraction in the cranial circulation whilst 5-HT 2 receptors, at which sumatriptan has no activity, mediate contraction within the peripheral vasculature.V":"
The discovery of sumatriptan stemmed from the knowledge that vasoconstrictor agents can alleviate migraine. Early studies by Graham and Wolff"? demonstrated a clear relationship between the ability of ergotamine to alleviate headache and its vasoconstrictor activity in the excessively pulsating superficial temporal artery. Intravenous administration of 5-HT itself will abort migraine headache."; this is thought to be attributable to vasoconstrictor activity although side effects, such as peripheral vasoconstriction, 100 0> J:
Migraine, serotonin and sumatriptan 11ñ ausea, vomiting and hyperpnoea, which accompany this treatment, reflect the ability of 5-HT to activate other 5-HT receptors ( Table 2) . The concept was developed that an agent which selectively constricted the cranial vasculature would provide an effective treatment for migraine;" It is now apparent that a means of achieving this profile of action is by use of a 5-HT t receptor agonist: sumatriptan represents the first example of this novel class of drug.
Clinical studies in over 7000 patients have shown that sumatriptan is highly effective in the acute treatment of migraine. Sumatriptan 6 mg. administered subcutaneously, caused a rapid onset of headache relief and by one hour after injection over 70°!c, of patients had an effective response to sumatriptan, compared to 25% on placebo (p<O.OOI; Figure 3 ). Two hours alter (x s) injection over 80% of patients obtained relief after a single 6 mg injection of sumatriptan compared to up to 37% on placebo (p<O.OOl).7.x An autoinjector device is available for patients to self-administer sumatriptan. This is advantageous for patients requiring rapid onset of effect, or for whom nausea and/or vomiting are prominent symptoms of the attack. In a clinical trial of 235 patients treating themselves at home, sumatriptan was shown to be as effective as when administered by a physician with over 80% of patients obtaining relief of headache by two hours, significantly higher efficacy than was seen in the placebo treated group (30%) (p<O.OO 1).4'1 Orally administered sumatriptan (100 mg) produced headache relief in 50-67% of patients at two hours and 71-78% of patients by four hours.v-" In addition to relief of headache, sumatriptan also provides significant relief of other migraine symptoms such as nausea, vomiting, photophobia and phonophobia.r'<v-" The compound is well tolerated with adverse events being mild, short-lived and requiring no specific therapy. 7-'1.51 What is the mechanism by which sumatriptan alleviates the symptoms of a migraine attack? A central analgesic action can be ruled out because the compound only very poorly penetrates the blood brain barrier and, in a range of animal tests, sumatriptan had no analgesic activity, even at very high doses.tt-? The headache of migraine is thought to be of vascular origin, resulting from oedematous, pain-sensitive vessels within the cranium (see section on 'Pathogenesis of migraine'). It therefore seems likely that sumatriptan is acting at the level of the blood vessel wall and by constricting these excessively dilated, oedematous cranial vessels, sumatriptan normalizes vessel diameter" (Figure 4 ). This leads to an attenuation of the firing of perivascular sensory afferent fibres and alleviation of the headache. If the increased flow of sensory nerve activity to the eNS is also responsible for the autonomic symptoms of migraine such as nausea and vomiting, it can be envisaged how by blocking the primary sensory input from the intracranial vasculature, sumatriptan also alleviates these symptoms. Importantly, sumatriptan does not modify cerebral blood flow in either animals or man. 24 S 1 This may reflect the inability of sumatriptan to effectively penetrate the blood brain barrier and therefore vascular tone of the resistance vessels within the cerebral circulation is unaffected. Indeed, in animal studies sumatriptan will constrict pial arteries when applied perivascularly but has no effect when administered intravenously.v It seems likely that the specific locus of action of sumatriptan is at the level of the large cerebral arteries, where the blood brain barrier may be more permeable and, as conduit vessels, these have little influence on cerebral blood flow. Additionally, sumatriptan may act within the meningeal circulation where endothelial cells are fenestrated and thus easily permeable. 56 Such a concept is supported by findings that in migraine patients sumatriptan constricts the middle cerebral artery without modifying cerebral blood f1oW. 24.57 An action of sumatriptan directly on trigeminal sensory nerve terminals within the cranial blood vessel wall has also been proposed? and thus, via activation of prejunctional 5-HT) receptors, sumatriptan could inhibit the release of sensory neuropeptides (Figure 4 ). Experimental data from animal studies, where trigeminal nerves to the dura are activated electrically to cause plasma protein extravasation, are in keeping with this proposal'" and indeed, prejunctional inhibitory 5-HT) receptors are known to occur on certain peripheral sympathetic nerves." The relative contribution of a vascular as opposed to a neuronal action as the primary mechanism is unknown and indeed both may be important. However, the weight of evidence, both in animals and man, demonstrates that the cranial vasoconstrictor activity of sumatriptan seems important for the anti migraine action of the compound.v' Nevertheless, future studies may reveal that an inhibitory effect on trigeminal nerve terminals also contributes towards the ability of sumatriptan to alleviate migraine. Indeed, the concept that inhibition of neuropeptide release from peripheral terminals of the trigeminal nerve could abort migraine headache offers exciting avenues of research for the future.
Clinical evidence for the ability of sumatriptan to interact with the trigeminovascular system comes from the finding that sumatriptan reduces the increase in CGRP levels in the plasma which occur during migraine headache.v' However, either vasoconstriction and/or inhibition of neuropeptide release could account for this observation. U ndoubtably clinical and animal studies will continue in order to further elucidate the mechanism of action of sumatriptan. Clinical studies have already demonstrated that sumatriptan provides an effective treatment for cluster headache" but its efficacy in other types of headache, including vasodilator drug-induced headache, will be interesting to determine. Such studies should shed more light on the pathogenesis of migraine itself.
Sumatriptan and ergotamine: comparison of their profile of action
Sumatriptan and ergotamine both cause vasoconstriction of cranial blood vessels, including cranial arteriovenous anastomoses. 4 1--43.S4 ,61k>2 Additionally, both compounds inhibit extravasation of plasma protein in dura following activation of trigeminal sensory nerves.t-" These observations indicate that ergotamine may alleviate migraine headache by a mechanism similar to that of sumatriptan, involving an action at the level of the cranial blood vessel. Whether or not ergotamine acts through the same receptor mechanism as sumatriptan to achieve this effect is at present unclear, although it appears that their vasoconstrictor action on cranial arteriovenous anastomoses is at least in part mediated through different receptors.s'<' A central site of action for ergotamine has also been proposed in migraine. Thus, in animal studies ergotamine, administered intravenously, will suppress the discharge of neurones in the lateral cervical nucleus of the spinal cord evoked by electrical stimulation of craniovascular structures. This effect of ergotamine is claimed to occur at clinically relevant doses, and suggests that the compound is having an inhibitory action on central pain processing pathways." There has been considerable debate as to the ability of ergotamine to penetrate the blood brain barrier and thus gain access to central structures. The physicochemical properties of ergotamine suggest that it is unlikely to penetrate the blood brain barriers' but [3H]-ergotamine can be detected in rat brain following oral administration of high doses.s' Additionally, ergotamine has been detected in human CSF after oral administration,6S although the specificity of the assay in this study has been questtoned.w It is therefore conceivable that small amounts of ergotamine may penetrate into the brain but whether or not a central action actually contributes towards its antimigraine action remains to be established. However, in support of a central mechanism, the related compound, dihydroergotamine, has been shown to bind to brain areas specifically involved in craniovascular pain pathways when administered intravenously to anaesthetized cats.>" As had been previously described, sumatriptan only poorly penetrates the blood brain barrier, making a central action highly improbable.v-v Interestingly, in support of this, preliminary data indicate that in contrast to ergotamine, intravenous administration of sumatriptan had no effect on neuronal discharge in the spinal cord evoked by stimulation of cranial vessels.>
Comparison of clinical efficacy
Ergotamine has been in use for the treatment of migraine for over 60 years. However, there are few well controlled studies from which its efficacy can be assessed. None of the published studies used IHS criteria for the diagnosis of migraine with the exception of one in which the efficacy of sumatriptan 100 mg and ergotamine 2 mg, plus caffeine 200 mg (as Cafergot), are compared.v Sumatriptan was significantly more effective than ergotamine. Headache relief two hours after entry to the study was obtained by 66% of sumatriptan-treated patients compared with 48% of ergotamine-treated patients (p<0.001). This difference was reproducible in all three attacks treated in the study. In addition, more patients rated sumatriptan good or excellent than ergotamine (52% versus 31% respectively). Sumatriptan also relieved the accompanying symptoms of nausea, vomiting, photophobia and phonophobia significantly more effectively than ergotamine which provoked nausea and vomiting in some patients. It is also said that in order to obtain effective relief of migraine symptoms, ergotamine should be taken at the onset of an attack.v? Interestingly, sumatriptan is equally effective at alleviating migraine whether taken early (within four hours after onset of symptoms) or late in an attack."
Comparison of safety profile The ergots
From this single dose study'" the limited efficacy of ergotamine has been established, but clinical experience over many years has revealed a variety of well documented adverse effects. These include peripheral vasoconstriction, parasthesiae, nausea and vomiting; the potentially serious nature of some of these effects requires the daily and weekly intake of ergotamine to be carefully limited. (' <J.711 Pharmacological studies have revealed that ergotamine, and related ergot alkaloids, have the ability to activate many different types of receptor including those for 5-HT (Table 3) . Thus, ergotamine is active at 5-HT J receptor subtypes, including the 5-HT 1C receptor where it behaves as a highly potent agonist, is a partial agonist at 5-HT 2 and o-adrenoceptors and activates dopamine receptors. )<J,411.72-74 A very similar profile of action is seen with dihydroergotamine (Table 3) .411,44 Sumatriptan has activity at 5-HT ID receptors 44,45: this receptor is pharmacologically very similar to the 5-HT J receptor mediating vasoconstriction, which has been called 5-HT,-like in the absence of definitive characterization. 53 Additionally, sumatriptan has weaker activity at 5-HT 1A receptors.s--e a receptor type located predominantly within the eNS. Since sumatriptan does not effectively penetrate into the brain,4J.52 this seems of little relevance to its actions in animals or man. Importantly and in marked contrast to ergotamine, sumatriptan has no activity at a wide range of other 5-HT and non-5-HT receptors (Table 3) ergotamine can be demonstrated in animal studies where unlike sumatriptan it causes marked pressor effects in pithed rats ( Figure 5 ) and has characteristic spasmogenic activity in isolated uterine smooth muscle." Therefore, it is this nonselective profile of action of ergotamine and hence its ability to activate a variety of receptors at relatively low doses which probably accounts for its adverse side effect profile in clinical use. Its peripheral vasoconstrictor action may be due, at least in part, to 5-HT z and e-adrenoceptor activation whilst its emetic effect may reflect dopamine receptor stimulation.
The finding that ergotamine and dihydroergotamine are highly potent agonists at the 5-HT l c receptor'" is of interest in view of a recent proposal" that stimulation of central 5-HT l c receptors may initiate migraine. This hypotheses stemmed principally from an observation by Brewerton et alJ' that m-chlorophenylpiperazine (mCPP) induced a high incidence of migraine-like headache following oral administration: of subjects with a personal or family history of migraine, 90% developed severe headache. mCPP has higher affinity for 5-HT l c receptors over other 5-HT 1 subtypes or 5-HT z receptors (see 76 for references). Further support for an involvement of 5-HT l c receptors in migraine came from the knowledge that pizotifen and cyproheptadine, used for the prophylactic treatment of migraine, are potent 5-HT l c receptor antagonists although both these agents have additional actions at other receptors. 39 The potent 5-HT 1c receptor agonist activity of ergotamine and dihydroergotamine would suggest that if 5-HT 1c receptor activation was a trigger for migraine, then these ergot alkaloids might be expected to produce rather than alleviate headache. Obviously an essential factor in this argument is the ability of ergotamine or dihydroergotamine to gain access to central 5-HT,c receptors in order to cause receptor activation: brain penetration by both compounds is thought to be low, but in view of their high potency at 5-HT 1c receptors, may be sufficient. 40 Acute use of either compound is only occasionally associated with headache, but chronic use of ergotamine can result in the phenomenon of 'ergotamine headache'. 78.79 Thus, with prolonged use, a pattern of daily headache develops which is only relieved by ergotamine. This is exacerbated if attempts are made to discontinue the drug and a cycle of headache/selfmedication develops. The ergotamine headache appears to be refractory to other forms of treatment and hospitalization is frequently required for ergotamine withdrawal. The mechanism of ergotamine withdrawal headache is unknown but has been suggested to reflect a central effect of the compound following accumulation and storage in the body. 79 Ergotamine has a relatively short plasma half-life (95 ± 30 minutesj.r" but a long duration of action and there is evidence for its accumulation in the body after repeat dosing." The possibility that with chronic use ergotamine levels in the CNS may reach those required for activation of central pain pathways is a plausible explanation. Whether under these conditions ergotamine could stimulate 5-HT l c receptors to have this effect is an intriguing possibility which would provide data in support of the hypothesis of Fozard and Grey.?"
Sumatriptan
The safety profile of sumatriptan has been established from single dose and multiple dose single attack studies, from studies in up to six acute attacks of migraine and from ongoing studies over two years. Adverse event reports were documented in these trials, some of which were related to the underlying condition and some were unrelated either to the condition or the trial medication. However, the inclusion of placebo in most studies enables an assessment to be made of those events most likely to be related to sumatriptan. With sumatriptan injection, the commonest event is injection site reaction which was reported in 40% of patients when the injection was physician administered. Kl Interestingly, when the injection was selfadministered using the autoinjector device, substantially fewer patients (10%) reported injection site discomfort." Other adverse events reported after sumatriptan injection are listed in Table 4 . Nausea and vomiting were reported more commonly with oral sumatriptan than with placebo, as was taste disturbance. However, in the early studies a dispersible formulation of sumatriptan was used which had an unpleasant bitter taste. This has now been replaced by a film-coated tablet to be swallowed whole, which has no taste. Other adverse events reported in studies of oral sumatriptan are listed in Table 5 . The majority of these reported events were mild or moderate in intensity and short-lived. None required specific therapy and few patients withdrew from clinical studies due to adverse experiences. There is as yet no clear understanding of the mechanisms causing these side effects of sumatriptan though studies are ongoing to attempt to provide explanations. There is no evidence of dose escalation when patients are given the opportunity to treat all Migraine, serotonin and sumatriptan 125 attacks over a six-month period,"? which indicates that sumatriptan has no addictive potential and reassuringly that tachyphylaxis and tolerance does not occur with chronic use.
Sumatriptan has a relatively short half-life (about two hours) whilst a migraine attack may last for up to 72 hours. A proportion of patients (30-45%) experience a recurrence of headache after initial relief with sumatriptan. Presumably this reflects in certain individuals the reemergence of craniovascular neurogenic inflammation and thus headache returns as the effect of the drug wears off. The median time to recurrence in one study was reported as 13 hours after a single 6 mg injection. 7 Specific studies have been designed to evaluate rigourously the incidence of recurrent headache and its response to a further dose of sumatriptan. The trials have yet to be reported; however, preliminary data from the oral multiple dose study revealed that 75% of patients responded to a further 100 mg dose of sumatriptan for the treatment of recurrence (Glaxo: data on file). The number of patients was too small to permit statistical analysis.
Summary
In conclusion, many advances are being made in our understanding of the mechanisms involved in a migraine attack. The initiating events, whilst being not clearly defined, would appear to be neuronal in origin. However, much evidence now points towards the cranial vasculature as the source of migraine headache; sterile neurogenic vasodilatation and extravasation in these vessels lead to centrally directed sensory nerve activation, probably via the trigeminal nerve, and the perception of pain. For many years, ergotamine has been the mainstay of clinical treatment for migraine, despite uncertain efficacy and an array of associated adverse effects. However, the recently developed selective 5-HT, receptor agonist, sumatriptan, provides a novel, highly effective treatment for migraine, relieving both the headache and associated symptoms such as nausea, vomiting, photophobia and phonophobia. Sumatriptan has a good safety profile and is well accepted by patients. Its mode of action in migraine is thought to result from an effect at the level of the 'inflamed' pain sensitive cranial vessel to reduce sensory nerve activation. Future studies with sumatriptan, both in migraine and in other types of headache, should lead to a greater understanding of the aetiology and pathogenesis of headache.
